A role for fulvestrant monotherapy in the first-line treatment of ER plus metastatic breast cancer?

被引：2
|
作者：
Mahtani, Reshma L. [1 ]
机构：
[1] Univ Miami Hlth Syst, Div Hematol Oncol, Sylvester Comprehens Canc Ctr, 1192 East Newport Ctr Dr, Deerfield Beach, FL 33442 USA
来源：
BREAST JOURNAL | 2020年 / 26卷 / 02期
关键词：
POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; ANASTROZOLE; ABEMACICLIB; THERAPY; COMBINATION; PALBOCICLIB;
D O I：
10.1111/tbj.13495
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：109 / 111
页数：3
相关论文
共 50 条
  • [41] First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis
    Liao, Weiting
    Huang, Jiaxing
    Wu, Qiuji
    Wen, Feng
    Zhang, Nan
    Zhou, Kexun
    Bai, Liangliang
    Li, Qiu
    BREAST CANCER, 2020, 27 (03) : 399 - 404
  • [42] First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis
    Weiting Liao
    Jiaxing Huang
    Qiuji Wu
    Feng Wen
    Nan Zhang
    Kexun Zhou
    Liangliang Bai
    Qiu Li
    Breast Cancer, 2020, 27 : 399 - 404
  • [43] Indirect comparison of pembrolizumab monotherapy versus nivolumab plus ipilimumab in first-line metastatic lung cancer
    Halmos, Balazs
    Burke, Thomas
    Kalyvas, Chrysostomos
    Insinga, Ralph
    Vandormael, Kristel
    Frederickson, Andrew
    Piperdi, Bilal
    IMMUNOTHERAPY, 2022, 14 (05) : 295 - 307
  • [44] Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer
    Ingle, JN
    Krook, JE
    Mailliard, JA
    Hartmann, LC
    Wieand, HS
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (06): : 498 - 501
  • [45] First-Line Treatment of Metastatic Pancreatic Cancer
    Tokh, Mohammed
    Bathini, Venu
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2012, 13 (02): : 159 - 162
  • [46] Activity and safety of biweekly docetaxel plus capecitabine as first-line treatment for patients with metastatic breast cancer.
    Llorca, C
    Mayordomo, J
    Adrover, E
    Alvarez, I
    Madroñal, C
    Burillo, M
    Sanz, J
    Lorenzo, A
    Palombo, H
    Janariz, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 73S - 73S
  • [47] Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients
    Poggio, Francesca
    Lambertini, Matteo
    Blondeaux, Eva
    Vaglica, Marina
    Levaggi, Alessia
    Pronzato, Paolo
    Del Mastro, Lucia
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (09) : 1153 - 1161
  • [48] Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
    Blancas, I.
    Olier, C.
    Conde, V.
    Bayo, J. L.
    Herrero, C.
    Zarcos-Pedrinaci, I.
    Carabantes, F.
    Baena-Canada, J. M.
    Cruz, J.
    Ruiz-Borrego, M.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [49] Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
    I. Blancas
    C. Olier
    V. Conde
    J. L. Bayo
    C. Herrero
    I. Zarcos-Pedrinaci
    F. Carabantes
    J. M. Baena-Cañada
    J. Cruz
    M. Ruiz-Borrego
    Scientific Reports, 11
  • [50] DURATION OF FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER
    Gennari, Alessandra
    Provinciali, Nicoletta
    BREAST, 2015, 24 : S31 - S31
12345